Chen Z, Zhou J, Xue F, et al. - Researchers conducted the study for analyzing the 2-year add-on impact of using low concentration atropine in poor responders of orthokeratology in myopic children. Axial elongation in 73 eyes of 73 patients who completed 3 years of orthokeratology (ortho-k) treatment has been retrospectively reviewed. Study participants were divided into two groups: orthokeratology and atropine (OKA) group (n = 37) being treated with nightly 0.01% atropine in addition to ortho-k treatment for another 2 years and orthokeratology (OK) group (n = 36) continued to be treated with ortho-k without atropine (phase 2). During the first, second and third year, respectively, the mean axial elongation was 0.47 ± 0.15, 0.21 ± 0.15, 0.23 ± 0.13 mm for the OKA group and 0.41 ± 0.09, 0.30 ± 0.11, 0.20 ± 0.13 mm for the OK group. As compared with ortho-k mono-therapy, combining 0.01% nightly atropine did not significantly change the 3-year axial elongation outcome for fast myopia progressors and poor responders of ortho-k.